The tweet was deleted by the author.
But we saved everything 🙂.
Jerry Walis, Senior Director of GxP Quality Systems at Cullinan Therapeutics, shares how living with multiple autoimmune diseases motivates him to make a difference for others. He joined Antoine Sreih, Vice President and Medical Director of Clinical Development, to discuss how personal experience informs their commitment to advancing therapies.
The initiative reflects the company's emphasis on empathy-driven innovation within its clinical development teams. Cullinan Therapeutics continues to highlight the value of lived experience in shaping its approach to patient-focused drug development.
Earlier this year, Cullinan Therapeutics outlined a novel biomarker approach to address immune reset in autoimmune diseases. The company has also pursued T cell engager therapies targeting B cells to tackle root causes of these conditions. These efforts come as Cullinan emphasizes patient experience within its development strategies.